EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN GREAT BRITAIN
May 21, 2023 - … EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN GREAT … … EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN GREAT … EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN GREAT …
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
May 15, 2023 - … Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease … Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease May 15, …
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023 - … Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD(tm) 2023 Annual Meeting … Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD(tm) 2023 Annual Meeting Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD(tm) 2023 Annual Meeting …
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
March 30, 2023 - … Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals … … Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals … Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals …
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 27, 2023 - … Biologics License Application for Lecanemab Designated for Priority Review by China National … Administration … Biologics License Application for Lecanemab Designated for Priority Review by China National … Products Administration Biologics License Application for Lecanemab Designated for Priority Review by China National …
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
January 26, 2023 - … Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted … Medicines Agency … Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted … Medicines Agency Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted …
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
March 29, 2023 - … may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, …
Lecanemab Receives Priority Review Status in Japan
January 29, 2023 - … Lecanemab Receives Priority Review Status in Japan … Lecanemab Receives Priority Review Status in Japan Lecanemab Receives Priority Review Status in Japan January …
Eisai Initiates BLA Submission of Data for Lecanemab in China
December 22, 2022 - … Eisai Initiates BLA Submission of Data for Lecanemab in China … Eisai Initiates BLA Submission of Data for Lecanemab in China Eisai Initiates BLA Submission of Data for Lecanemab in China December 22, 2022 News Release General …
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
March 5, 2023 - … Priority Review for Traditional Approval of LEQEMBI(tm) ( lecanemab -irmb) for the Treatment of Alzheimer's Disease … … Priority Review for Traditional Approval of LEQEMBI(tm) (lecanemab-irmb) for the Treatment of Alzheimer's Disease FDA … Priority Review for Traditional Approval of LEQEMBI(tm) (lecanemab-irmb) for the Treatment of Alzheimer's Disease …